- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02634710
Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Pilot Study Evaluating Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND OVERVIEW: Hypofractionation has several potential advantages over conventional radiation. First, the biological equivalent dose to the tumor is higher with hypofractionation than it is with conventional radiation. In between radiation treatments there is repair of the radiation damaged cancer cells (on a cell survival curve this region of repair is referred to as the "shoulder" of the curve). Some cell lines are better at repair than others. Sarcoma is often referred to as a "radioresistant" tumor, which means that sarcoma cell lines have a larger capacity for radiation repair than do other cell lines. A treatment that can deliver a high dose in fewer fractions can potentially overcome some of this repair. There is a concept in radiation known as "biologically equivalent dose" (BED) which states that a higher dose per fraction results in more tumor kill than a lower dose per fraction. For example, radiation delivered to a total of 60 Gy in three 20 Gy fractions is the equivalent of 150 Gy in 2 Gy fractions.
BACKGROUND RATIONALE: It is important to conduct this study because hypofractionation not only decreases treatment package time and cost of care, but it also potentially improves patient convenience and quality of life and could impact radiologic and pathologic variables in a positive way by leading to more tumor cell kill. This could potentially change the paradigm of the current management of STS of the extremity and chest-wall.
HYPOTHESIS: Preoperative hypofractionated radiation therapy for localized soft tissue sarcomas (STS) will result in local control and toxicity similar to conventional fractionation with less cost, more patient convenience and decreased overall treatment time.
TREATMENT: Image-guided radiation therapy is mandatory. PREOPERATIVE: (1) Either 3D conformal radiotherapy or intensity modulated radiation therapy (IMRT). (2) A prescription dose of 35 Gy in 5 fractions given every other day with at least 48 hours in between each fraction will be prescribed to cover 95% of the planning target volume. TREATMENT SCHEDULE: Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years of age
- Core needle biopsy obtained
- Pathologic confirmation of primary soft tissue sarcoma of the upper or lower extremity or chest-wall.
- Stage I-III Soft Tissue Sarcoma of the extremity without evidence of metastatic disease
- Medically operable
- No prior radiotherapy to primary site or adjacent site that results in overlapping radiation fields.
- MRI obtained of the affected extremity or chest-wall
- CT chest acquired to assess distant disease
- Karnofsky Performance Status (KPS) 60 or above
- Informed consent obtained prior to study entry
Exclusion Criteria:
- Patients who have metastatic disease
- Pregnant women
- Women of childbearing potential and male participants must practice adequate contraception.
- Disease pathology other than sarcoma subtypes
- Patients with a history of metastatic disease from a primary other than sarcoma
- Patients who cannot undergo MRI as part of pre-treatment or treatment planning process
- STS of non-extremity or chest-wall regions
- Tumor size ≥ 20 cm maximal dimension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypofractionated Radiation Therapy
Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day.
Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
|
Treatments will have a minimum of a 48-hour interfraction interval.
Treatments will be completed over 20 days maximum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Disease Control Assessed by Physical Examination
Time Frame: 2 Years
|
This measure will capture the number of subjects experiencing a recurrence of the primary lesion assessed by physical examination.
|
2 Years
|
Local Disease Control Assessed by Magnetic Resonance Imaging (MRI)
Time Frame: 2 years
|
This measure is the number of subjects experiencing a recurrence of the primary lesion as assessed by MRI.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Musculoskeletal Tumor Rating Scale (MSTS) Score
Time Frame: Baseline (typically 2 to 4 weeks prior to surgery) and 4, 8, 12, 16, 20, and 24 months after surgery
|
Toxicity will be assessed at specific times the Musculoskeletal Tumor Rating Scale.
The MSTS evaluates: pain, function, emotional acceptance, hand positioning, dexterity and lifting ability, using a six-item Likert scale ranging from 0 (worst condition) to 5 (best condition).
The individual scores are added for the MSTS Score, range 0 to 30.
A higher score indicates better function.
|
Baseline (typically 2 to 4 weeks prior to surgery) and 4, 8, 12, 16, 20, and 24 months after surgery
|
Disease-free Survival
Time Frame: 2 Years
|
Disease-free survival will measure the time in months from initiation of radiation therapy until documented recurrence of disease.
Patients who are disease-free and alive at the time of analysis will be censored at the time of their last follow-up.
Patients will be assessed for disease-free survival at 2 years.
|
2 Years
|
Overall Survival
Time Frame: 2 Years
|
Overall survival will measure the time from initiation of radiation therapy until documented death from any cause.
Patients who are alive at the time of analysis will be censored at the time of their last follow-up.
Patients will be assessed for overall survival at 2 years.
|
2 Years
|
Radiologic Changes Due to Hypofractionated Radiation.
Time Frame: 4 weeks after radiation therapy
|
This measure will assess the presence or absence of enhancement of T2 imaging.
|
4 weeks after radiation therapy
|
Pathologic Changes Due to Hypofractionated Radiation.
Time Frame: 2 weeks after surgery
|
This measure will capture the fibrosis present in tissue specimens as a percent.
|
2 weeks after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Meena Bedi, MD, Medical College of Wisconsin
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 25722
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
Clinical Trials on Hypofractionated Radiation Therapy
-
University of UtahNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Endometrial CarcinomaUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina
-
University of UtahActive, not recruitingStage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In SituUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC...United States
-
Changhai HospitalRecruiting
-
Medical University of South CarolinaRecruitingSoft Tissue SarcomaUnited States
-
Jiangsu Cancer Institute & HospitalActive, not recruitingLung Cancer, Non-small CellChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
University of Colorado, DenverActive, not recruitingBreast CancerUnited States
-
Samsung Medical CenterRecruitingRadiotherapy Side EffectKorea, Republic of